OKYO Says its Anti-inflammatory Dry Eye Candidate Also Reduces Ocular Pain

OKYO Pharma, of London, announced Dec. 13 that its first drug candidate, OK-101, developed to treat dry eye disease as an anti-inflammatory, also showed potent ocular pain reducing properties in a mouse model. OK-101 is a novel, long-acting G protein-coupled receptor-based lipidated chemerin peptide developed to bind to ChemR23 receptors in the eye and interrupt the inflammatory response.

Kiora Reports KIO-101 is Safe and Tolerable for Dry Eye Disease

Kiora Pharmaceuticals announced topline data from its vehicle-controlled, randomized safety study of KIO-101 eyedrops. The study evaluated 24 healthy subjects and 21 patients diagnosed with ocular surface inflammation, a driver of dry eye disease. The results demonstrated favorable safety and tolerability of KIO-101 as well as statistically significant improvements in conjunctival hyperemia, a key inclusion criterion for the 21 patients …

Stuart Therapeutics Completes Enrollment in Phase II Trial for Dry Eye Candidate

Stuart Therapeutics, of Stuart, Florida, announced Sept. 8 that it had completed enrollment of 150 patients in a Phase II clinical trial of its eye drop candidate ST-100 in dry eye disease. The multi-center, randomized, double-masked study will evaluate two different dose levels vs. placebo.  The company, founded in 2017, has exclusively licensed the worldwide rights to a family of …

Low-Level Light Therapy

This procedure is a simple and effective option for treating meibomian gland dysfunction. Many options are available for the treatment of meibomian gland dysfunction (MGD), but most insurance plans cover only pharmaceuticals. Low-level light therapy (LLLT) is a low-cost entry point to MGD management. It is effective both as a standalone procedure with the Equinox (Espansione Group) and in combination …